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Abstract
Background: The significance of the expression of aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker,
for predicting the recurrence of estrogen receptor (ER)-positive/human epidermal growth factor receptor type 2
(HER2)-negative breast cancer is still poorly understood. The value of ALDH1 in predicting the time of recurrence
remains unknown.
Methods: In total, 184 patients with early distant recurrence, 134 patients with late distant recurrence, and 321 control
patients without recurrence for more than 10 years after starting initial treatment for ER-positive/HER2-negative breast
cancer, registered in 9 institutions, were analyzed. We assessed relationships between ALDH1 and other
clinicopathological features, and ALDH1 expression was compared among the three groups. The relationship
between ALDH1 expression and overall survival after recurrence was also evaluated in each group.
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Results: The rates of ALDH1 expression positivity (more than 1 %) in the early, late, and no recurrence groups were 18.
4 %, 13.4 %, and 8.4 %, respectively. ALDH1 expression correlated significantly with lymph node metastases (p = 0.048)
and the Ki-67 labeling index (p < 0.001) in the early recurrence group. Multivariate analysis revealed ALDH1 expression to
be significantly higher in the early recurrence group than in the no recurrence group (adjusted OR 2.140, 95 % CI
1.144–4.003, p = 0.016). Moreover, there was a significant difference in ALDH1 expression between the early and no
recurrence groups receiving adjuvant endocrine therapy and chemotherapy (adjusted OR 4.625, 95 % CI 1.881–12.474,
p < 0.001). However, there was no difference in ALDH1 expression between the late and no recurrence groups in univariate
analysis (OR 1.507, 95 % CI 0.738–2.998, p= 0.253). In multivariate analysis, ALDH1 was not a factor independently predicting
overall survival after the detection of recurrence (adjusted OR 1.451, 95 % CI 0.985–2.085, p = 0.059).
Conclusions: Among patients with ER-positive/HER2-negative breast cancer, ALDH1 expression was more common in
those with early recurrence, and this expression was found to be associated with a more aggressive breast cancer
phenotype than that in the patients without recurrence. Further study is needed to clarify the prognostic significance
of the heterogeneity of cancer stem cells and to confirm their role in resistance to chemotherapy.
Keywords: Breast cancer, Estrogen receptor-positive, Human epidermal growth factor receptor type 2-negative,
Aldehyde dehydrogenase 1, Time of recurrence
Background
For patients with estrogen receptor (ER)-positive/human
epidermal growth factor receptor 2 (HER2)-negative
breast cancer receiving adjuvant chemotherapy, endo-
crine therapy for 5 years plus additional chemotherapy
for high-risk groups, such as patients with high tumor
burden, advanced histological grade, and/or strong Ki-67
expression, is considered to improve survival. This com-
bined treatment strategy was proven to be effective in
reducing the risk of recurrence within the first 5 years
after diagnosis [1]. However, some tumors give rise to
recurrence regardless of adjuvant therapy, and there are
reports indicating the efficacy of chemotherapy to be less
for patients with ER-positive breast cancer than for those
with ER-negative breast cancer [2]. Furthermore, women
with ER-positive breast cancer remain at particularly
high risk of late recurrence, which is defined as relapse
more than 5 years after initial treatment, and prolongation
of endocrine treatment duration is thus under discussion
[3]. Therefore, accurate and reliable estimates of the risk
of recurrence after 5 years of endocrine therapy are neces-
sary for making the most appropriate decisions regarding
extended endocrine therapy. Tumor size and nodal metas-
tases were previously reported to be predictive factors for
early and late recurrence of ER-positive/HER2-negative
tumors [4, 5]. The gene signature assay, homeobox/inter-
leukin-7 ratio, Breast Cancer Index (Biotheranostics, San
Diego, CA, USA), Prosigna assay (NanoString Technolo-
gies, Seattle, WA, USA), Oncotype DX assay (Genomic
Health, Redwood City, CA, USA), and EndoPredict test
(Sividon Diagnostics, Cologne, Germany) have all been
employed in efforts to predict early and late recurrence
events in patients with breast cancer. Risk factors reliably
associated with not only early but also late recurrence need
to be determined, and those patients who would benefit
from extended endocrine therapy must be identified.
Recently, aldehyde dehydrogenase 1 (ALDH1) was
recognized as a cancer stem cell marker [6]. ALDH1 is a
detoxifying enzyme that oxidizes aldehyde and thereby
impacts resistance to alkylating agents [7]. ALDH1 also
converts retinol into retinoic acid. Retinoic acid, which
is a modulator of cell proliferation, might influence the
proliferation of cancer stem cells [8]. Therefore, ALDH1-
positive cells may contribute to the development of re-
sistance to adjuvant chemotherapeutic agents and the
aggressiveness of malignant tumors [9–12]. In a clinical
study, Ginestier et al. initially found ALDH1-positive
tumor cells to be associated with poor clinical outcomes
[6]. Morimoto et al.’s report also showed ALDH1-positive
breast cancers to have an aggressive phenotype [13]. Dong
et al. reported ALDH1 expression to be an independent
predictor of poor outcomes in patients with breast cancer
[14]. However, in other previous studies, researchers
found ALDH1 expression to be associated with good out-
comes. Thus, the significance of ALDH1 expression as a
predictor of the recurrence period for ER-positive/HER2-
negative breast cancer has yet to be elucidated.
Previously, we investigated clinicopathological factors
predictive of early and late recurrence in ER-positive/
HER2-negative breast cancer cases in a joint multi-
institutional study carried out by the Collaborative Study
Group of the Scientific Research of the Japanese Breast
Cancer Society. The results of that study suggest that
predictors of early and late distant recurrence may differ
according to menopausal status and age [15]. We next
explored a new biomarker for predicting the recurrence
period in the same cohort. We noted that cancer stem
cells could remain in a dormant state and thereby escape
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the effects of adjuvant therapy. Such cells might grow
relatively slowly for a long period and eventually become
detectable metastatic tumors. We hypothesized that
ALDH1 expression in the primary lesion correlates with
early and late recurrence of ER-positive/HER2-negative
breast tumors. We retrospectively collected data from ER-
positive/HER2-negative breast cancer cases with early and
late distant recurrence and from patients who remained
recurrence-free for more than 10 years. We compared
ALDH1 expression levels among these three groups. The
relationship between ALDH1 expression and overall sur-
vival after recurrence was also evaluated.
Methods
Cases and clinical samples
In total, 223 consecutive patients with early distant re-
currence and 149 consecutive patients with late distant
recurrence of ER-positive/HER2-negative breast cancer,
who had undergone breast surgery and/or neoadjuvant
chemotherapy between January 2000 and December
2004, were registered from 9 institutes. These institutes
were Okayama University, Cancer Institute Hospital,
Japanese Foundation for Cancer Research, the Hokkaido
University Institutional Review Board (IRB), Juntendo
University, National Health Organization (NHO) Osaka
National Hospital, Kumamoto University, Kumamoto City
Hospital, NHO Hokkaido Cancer Center, and Nagoya City
University. This was a joint multi-institutional study titled
Analysis of Biological Characteristics and Factors Pre-
dicting Late Recurrence in Breast Cancer, carried out
by the Collaborative Study Group of Scientific Research
of the Japanese Breast Cancer Society. Early recurrence
was defined as being within 5 years of initial treatment,
late recurrence as more than 5 years after initial treat-
ment. For each late recurrence patient, approximately
two age-matched patients free of recurrence for more
than 10 years were randomly selected using the RAND
function in Excel software (Microsoft, Redmond, WA,
USA) at each institution. In total, 321 patients who had
been recurrence-free for more than 10 years served as
study controls. The study protocol was approved by the
IRB of each participating institution and conformed to
the guidelines of the 1996 Declaration of Helsinki.
Informed consent was obtained from some of the patients.
However, opting out and a waiver of informed consent
were options, as anonymized archival specimens were
used in this retrospective study.
Among the registered patients, formalin-fixed, paraffin-
embedded samples (n = 184 early recurrence, n = 134 late
recurrence, n = 321 no recurrence) were available from
639 individuals. ALDH1 expression rates were compared
among the three groups. We also assessed the relation-
ships between ALDH1 and other clinicopathological
features. Moreover, the relationship between ALDH1
expression and overall survival after recurrence was
evaluated for each of the groups.
Immunohistochemical staining and scoring for ER,
progesterone receptor, HER2, and Ki-67 expression
Expression of ER, progesterone receptor (PgR), HER2,
and Ki-67 were centrally assessed with immunohisto-
chemical (IHC) staining techniques. IHC staining was
performed on formalin-fixed, paraffin-embedded sec-
tions (3–4 μm). The primary antibodies used included
monoclonal mouse antihuman ERα antibody (1D5;
Dako, Glostrup, Denmark) at a 1:100 dilution for ER,
monoclonal mouse antihuman PgR antibody (636; Dako)
at a 1:100 dilution for PgR, and monoclonal mouse anti-
human Ki-67 antibody (MIB-1; Dako) at a 1:200 dilution.
ER was considered to be positive if nuclear staining
exceeded 1 %. The Ki-67 labeling index was assessed as
the percentage of tumor cells showing definite nuclear
staining among more than 1000 invasive tumor cells.
HER2 immunostaining was evaluated using the Her-
cepTest (Dako). Tumors with a score of 2+ were tested
for gene amplification by in situ hybridization (ISH).
Tumors were considered to be HER2-positive if IHC
staining was scored 3+ or if ISH results were positive.
ER-negative and/or HER2-positive tumors were ex-
cluded from this study.
IHC staining and scoring for ALDH1
IHC staining of formalin-fixed, paraffin-embedded sec-
tions (thickness:3–4 μm) was performed. Mouse anti-
ALDH1 antibody (aa 7–128, catalog number 611195; BD
Biosciences, San Jose, CA, USA) was diluted 1:1000. An
immunohistochemistry kit containing horse serum block-
ing liquid and secondary antibody (catalog number MP-
7402; Vector Laboratories, Burlingame, CA, USA) and A
3,3′-diaminobenzidine (DAB) kit (catalog number SK-
4105; Vector Laboratories) were used. Antigen retrieval
was performed in citrate buffer according to the manufac-
turer’s protocol. The diluted ALDH1 antibody was added
to the available specimens and left standing for 1 h at
room temperature. PBS, instead of the first antibody, was
added to the specimens used as negative controls. Liver
tissue specimens were also used as known positive con-
trols for IHC staining. Secondary antibody and HRP-
labeled streptavidin were added to the breast cancer
specimens, followed by DAB color rendering and coun-
terstaining with hematoxylin. ALDH1 staining of tumor
cells was considered to be positive when the cytoplas-
mic cellular components showed a positive reaction.
Special attention was paid to stromal cells, lympho-
cytes, and histiocytes because such cells show cross-
reactions with ALDH1. Therefore, hematoxylin and
eosin-stained sections were also used to distinguish
ALDH1-positive tumor cells from other stained cells.
Miyoshi et al. Breast Cancer Research  (2016) 18:73 Page 3 of 12
One investigator scored ALDH1 expression rates. How-
ever, unclear findings, especially when it was difficult to
distinguish ALDH1-positive tumor cells from other
positive cells, were encountered. Such findings were
discussed with both another investigator and one path-
ologist, employing a multihead microscope. Differences of
opinion were resolved by discussion until consensus was
reached.
Statistical analysis
Differences in clinicopathological data were compared
with the chi-square test. In the comparison between
cases with recurrent disease and the recurrence-free pa-
tients, the ORs for different variables were assessed by
applying a logistic regression model in univariate and
multivariate analyses. The Kaplan-Meier method was
used to estimate overall survival from the time of recur-
rence. Differences between overall survival curves were
determined with a log-rank test. For both univariate and
multivariate analyses, Cox regression was used to evalu-
ate the influence of the variables on survival. All of the
data were analyzed with the use of JMP 11.0.0 statistical
software (SAS Institute, Cary, NC, USA). p < 0.05 was
considered to indicate a statistically significant difference.
Results
Patient characteristics
Patient characteristics are presented in Table 1. The me-
dian follow-up durations were 72 (range 14–179) months,
133 (range 67–177) months, and 128 (range 57–179)
months in the early, late, and no recurrence groups, re-
spectively. During follow-up of these 639 patients, 69.5 %
(128 of 184) of those with early recurrence and 31.3 %
(42 of 134) of those with late recurrence died as a result
of breast cancer. The histology was invasive ductal car-
cinoma in 94.0 % (173 of 184), 93.2 % (125 of 134), and
93.1 % (299 of 321) of the early, late, and no recurrence
groups, respectively. The recurrences were local in
20.1 % (37 of 184) of the early recurrence group and in
28.3 % (38 of 134) of the late recurrence group. Adju-
vant endocrine therapy alone had been administered to
28.8 % (53 of 184) of early recurrence patients, 41.0 %
(55 of 134) of late recurrence patients, and 56.0 % (180
of 321) of control patients, while 53.8 % (99 of 184),
51.4 % (69 of 134), and 32.3 % (104 of 321), respectively,
received both adjuvant chemotherapy and endocrine
therapy. The adjuvant chemotherapy consisted mainly
of anthracyclines and/or taxanes.
Distributions of ALDH1-positive cells
The majority of specimens contained no ALDH1-positive
cells, though some showed a patchy epithelial pattern and
identifiable hot spots. ALDH1 expression in all or most of
the cells in a hot spot was rare. We evaluated the
proportion of ALDH1-positive cells in one hot spot, since
cancer stem cells represent only a small fraction of the cell
population in a tumor. A representative staining pattern
in a breast cancer specimen is shown in Fig. 1. The pro-
portions of ALDH1-positive cells were 0–1 % in 560 cases
(early recurrence 81.5 % [150 of 184], late recurrence
86.6 % [116 of 134], no recurrence 91.6 % [294 of 321]),
1–5 % in 47 cases (early recurrence 11.4 % [21 of 184], late
recurrence 10.4 % [14 of 134], no recurrence 3.7 % [12 of
321]), and 5–100 % in 32 cases (early recurrence 7.0 % [13
of 184], late recurrence 2.9 % [4 of 134], no recurrence
4.6 % [15 of 321]). Only 11 cases showed more than 20 %
of tumor cells to be ALDH1-positive (early recurrence
0.6 % [4 of 184], late recurrence 0.3 % [2 of 134], no recur-
rence 0.7 % [5 of 321]). In many previous studies, 5 %
cutoff points were adopted, but there were few ALDH1-
positive cases among those with ER-positive/HER2-
negative breast cancer. In the present study, cases with
ALDH1-positive rates exceeding 5 % were also very
few. We regarded positive cases as those in which more
than 1 % of cells were ALDH1-positive, because even a
small fraction of cancer stem cells might be an important
factor. On the basis of our chi-square test employing the
1 % cutoff value, differences among the three groups were
statistically significant (p = 0.004).
Associations of ALDH1 expression with
clinicopathological factors
We assessed whether ALDH1 expression was associated
with clinicopathological factors (Table 2). Both tumor size
and nodal metastasis were evaluated clinically. ALDH1
expression in breast cancer specimens correlated signifi-
cantly with nodal metastasis (p = 0.047) and high Ki-67 ex-
pression (p < 0.001) in the early recurrence group. Age
(p = 0.077), nodal metastasis (p = 0.065), and tumor
grade (p = 0.058) showed no associations with ALDH1
expression in the late recurrence group. Similarly, no
significant differences were detected in the recurrence-
free group.
Comparison of ALDH1 expression in the early and no
recurrence groups
ALDH1 expression was significantly higher in the
early recurrence group than in the no recurrence
group (p = 0.001). We selected significant parameters
(p < 0.20) from among the potentially confounding
factors and performed a multivariate analysis in which
bilateral breast cancer, age, tumor size, nodal metasta-
sis, tumor grade, and Ki-67 served as categorical variables.
Bilateral breast cancer (p < 0.001), tumor size (p < 0.001),
nodal metastasis (p < 0.001), tumor grade (p = 0.006), and
ALDH1 expression (p = 0.016) were significant factors
predicting early recurrence in the multivariate analysis
(Table 3).
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Table 1 Clinicopathological factors according to time of recurrence
p Values
Early recurrence
(n = 184)
Late recurrence
(n = 134)
No recurrence
(n = 321)
Early vs no
recurrence
Late vs no
recurrence
Early vs late
recurrence
Age, years
≤ 50 82 (44.57) 49 (36.57) 120 (37.38) 0.113 0.869 0.151
> 50 102 (55.43) 85 (63.43) 201 (62.62)
Menopausal status
Postmenopausal 90 (48.91) 81 (60.45) 171 (53.27) 0.345 0.159 0.041
Premenopausal 94 (51.09) 53 (39.55) 150 (46.73)
Bilateral breast cancer
Absent 169 (91.85) 121 (90.30) 319 (99.38) <0.001 <0.001 0.631
Present 15 (8.15) 13 (9.70) 2 (0.62)
Tumor size, mm
≤ 20 49 (26.63) 44 (32.84) 187 (58.26) <0.001 <0.001 0.23
> 20 135 (73.37) 90 (67.16) 134 (41.74)
Nodal metastasis
Negative 93 (50.54) 79 (58.96) 267 (83.18) <0.001 <0.001 0.136
Positive 91 (49.46) 55 (41.04) 54 (16.82)
Histological type
IDC-NST 171 (92.93) 124 (92.54) 297 (92.52) 0.864 0.995 0.892
Others 13 (7.07) 10 (7.46) 24 (7.48)
Estrogen receptor staining
< 10 % 16 (8.70) 10 (7.46) 27 (8.41) 0.396 0.367 0.915
10–50 % 57 (30.98) 43 (32.09) 82 (25.55)
≥ 50 % 111 (60.33) 81 (60.45) 212 (66.04)
Progesterone receptor
staining
≤ 20 % 85 (46.20) 59 (44.03) 133 (41.43) 0.298 0.609 0.701
> 20 % 99 (53.80) 75 (55.97) 188 (58.57)
Tumor grade
1 or 2 131 (71.20) 106 (79.10) 278 (86.60) <0.001 0.049 0.107
3 53 (28.80) 28 (20.90) 43 (13.40)
Ki-67 staining
≤ 20 % 136 (73.91) 114 (85.07) 265 82.55) 0.022 0.507 0.014
> 20 % 48 (26.09) 20 (14.93) 56 (17.45)
Local recurrence
Absent 136 (78.61) 96 (71.64) 0
Present 37 (21.39) 38 (28.36) 0
Surgical treatment
Total mastectomy 117 (63.59) 78 (58.21) 106 (33.02) 0.076 <0.001 0.331
Partial mastectomy 67 (36.41) 56 (41.79) 215 (66.98)
Radiation therapy
Absent 100 (54.35) 92 (68.66) 149 (46.42) <0.001 <0.001 0.009
Present 84 (45.65) 42 (31.34) 172 (53.58)
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Comparison of ALDH1 expression in the late and no
recurrence groups
The univariate analysis revealed no significant difference
in ALDH1 expression between the late and no recur-
rence groups (p = 0.110). We performed a multivariate
analysis in which bilateral breast cancer, menopausal sta-
tus, tumor size, nodal metastasis, and tumor grade served
as categorical variables. In this multivariate analysis, the
relationship between ALDH1 expression and late recur-
rence did not reach statistical significance (p = 0.253)
(Table 4).
Comparison of ALDH1 expression in the early and late
recurrence groups
Employing the chi-square test, the univariate analysis re-
vealed no significant difference in ALDH1 expression
Table 1 Clinicopathological factors according to time of recurrence (Continued)
Adjuvant treatment
None 13 (7.07) 4 (2.99) 30 (9.35) <0.001 <0.001 0.021
Chemotherapy only 19 (10.33) 6 (4.48) 7 (2.18)
Endocrine therapy only 53 (28.80) 55 (41.04) 180 (56.07)
Combined therapy 99 (53.80) 69 (51.49) 104 (32.40)
Neoadjuvant chemotherapy
Absent 168 (91.30) 131 (97.76) 305 (95.31) 0.076 0.198 0.011
Present 16 (8.70) 3 (2.24) 15 (4.69)
Chemotherapy
A + T 54 (29.35) 22 (16.42) 42 (13.08)
A 39 (21.20) 31 (23.13) 40 (12.46)
T 6 (3.26) 7 (5.22) 13 (4.05)
CMF 17 (9.24) 12 (8.96) 13 (4.05)
Other 2 (1.09) 3 (2.24) 3 (0.93)
None 66 (35.87) 59 (44.03) 210 (65.42)
Endocrine therapy
TAM 61 (33.15) 34 (25.37) 68 (21.18)
TAM + LHRH 30 (16.30) 18 (13.43) 35 (10.90)
TAM→ AI 16 (8.70) 36 (26.87) 72 (22.43)
TAM + LHRH→ AI 1 (0.54) 3 (2.24) 15 (4.67)
AI 39 (21.20) 27 (20.15) 87 (27.10)
LHRH 5 (2.72) 6 (4.48) 7 (2.18)
None 32 (17.39) 10 (7.46) 37 (11.53)
Abbreviations: IDC-NST invasive ductal carcinoma of no special type, A + T anthracycline and taxane, A anthracycline, T taxane, CMF cyclophosphamide,
methotrexate, and fluorouracil, TAM tamoxifen, TAM + LHRH tamoxifen and luteinizing hormone-releasing hormone, TAM→ AI tamoxifen followed by aromatase
inhibitor, TAM + LHRH→ AI tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor, AI aromatase inhibitor, LHRH luteinizing
hormone-releasing hormone
Fig. 1 Immunohistochemical staining of aldehyde dehydrogenase 1 (ALDH1) in breast tumor cells. a Essentially all of the tumor cells are positive
for ALDH1. b No ALDH1-positive cells are present
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between the early and late recurrence groups (p = 0.225)
(Table 1). An OR was not calculated, because ALDH1
was not selected as a significant parameter (p < 0.20).
Comparison of ALDH1 expression between the early and
no recurrence groups receiving chemotherapy and
endocrine therapy
We analyzed 203 cases (99 early recurrence, 104 no recur-
rence) administered both endocrine therapy and chemo-
therapy to compare clinicopathological factors (Table 6).
Tumor size (p = 0.004), nodal metastasis (p < 0.001), tumor
grade (p = 0.007), and ALDH1 expression (p < 0.001) dif-
fered significantly between these early and no recurrence
groups by univariate analysis. We selected significant pa-
rameters (p < 0.20) from among the various conventional
confounding factors and performed a multivariate analysis
in which age, clinical tumor size, clinical nodal metastasis,
tumor grade, and Ki-67 expression served as categorical
variables. This multivariate analysis revealed tumor size
(p = 0.044), nodal metastasis (p < 0.001), and ALDH1
Table 2 Associations of aldehyde dehydrogenase 1 expression with clinicopathological factors according to time of recurrence
Early recurrence Late recurrence No recurrence
ALDH1+ ALDH1− p Value ALDH1+ ALDH1− p Value ALDH1+ ALDH1− p Value
Age, years
≤ 50 15 (44.12) 67 (44.67) 0.981 10 (55.56) 39 (33.62) 0.077 12 (44.44) 108 (36.73) 0.432
> 50 19 (55.88) 83 (55.33) 8 (44.44) 77 (66.38) 15 (55.56) 186 (63.27)
Tumor size, mm
≤ 20 9 (26.47) 40 (26.67) 0.981 4 (22.22) 40 (34.48) 0.288 15 (55.56) 172 (58.50) 0.766
> 20 25 (73.53) 110 (73.33) 14 (77.78) 76 (65.52) 12 (44.44) 122 (41.50)
Lymph node metastasis
Negative 12 (35.29) 81 (54.00) 0.047 7 (38.89) 72 (62.07) 0.065 23 (85.19) 244 (82.99) 0.767
Positive 22 (64.71) 69 (46.00) 11 (61.11) 44 (37.93) 4 (14.81) 50 (17.01)
Estrogen receptor staining
< 10 % 3 (8.82) 13 (8.67) 0.559 2 (11.11) 8 (6.90) 0.335 3 (11.11) 24 (8.16) 0.831
10–50 % 8 (23.53) 49 (32.67) 8 (44.44) 35 (30.17) 6 (22.22) 76 (25.85)
≥ 50 % 23 (67.65) 88 (58.67) 8 (44.44) 73 (62.93) 18 (66.67) 194 (65.99)
Progesterone receptor staining
≤ 20 % 14 (41.18) 71 (47.33) 0.514 7 (38.89) 52 (44.83) 0.635 13 (48.15) 120 (40.82) 0.461
> 20 % 20 (58.82) 79 (52.67) 11 (61.11) 64 (55.17) 14 (51.85) 174 (59.18)
Histological grade
1 or 2 25 (73.53) 106 (70.67) 0.736 11 (61.11) 95 (81.90) 0.058 25 (92.59) 253 (86.05) 0.305
3 9 (26.47) 44 (29.33) 7 (38.89) 21 (18.10) 2 (7.41) 41 (13.95)
Ki-67 staining
≤ 20 % 17 (50.00) 119 (79.33) <0.001 14 (77.78) 100 (86.21) 0.373 20 (74.07) 245 (83.33) 0.247
> 20 % 17 (50.00) 31 (20.67) 4 (22.22) 16 (13.79) 7 (25.93) 49 (16.67)
ALDH1 aldehyde dehydrogenase 1
Table 3 Univariate and multivariate analyses for early recurrence in all cases (early vs no recurrence)
Early vs no recurrence
Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 2.468 (1.438–4.274) 0.001 2.140 (1.149–4.003) 0.016
Bilateral breast cancer absent/present 14.156 (3.932–90.478) <0.001 16.434 (4.111–110.886) <0.001
Age, ≤50/>50 years 0.742 (0.513–1.073) 0.113 0.748 (0.490–1.142) 0.178
Tumor size ≤20/>20 mm 3.844 (2.604–5.745) <0.001 2.692 (1.747–4.181) <0.001
Nodal metastasis negative/positive 4.838 (3.220–7.336) <0.001 3.728 (2.383–5.876) <0.001
Tumor grade 1 or 2/3 2.615 (1.666–4.128) <0.001 2.063 (1.230–3.470) 0.006
Ki-67 staining <20 %/≥20 % 1.670 (1.076–2.586) 0.022 0.855 (0.506–1.427) 0.551
ALDH1 aldehyde dehydrogenase 1
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expression (p < 0.001) to be significant factors predicting
early recurrence (Table 5).
Comparison of ALDH1 expression between the early and
no recurrence groups receiving endocrine therapy alone
We analyzed 233 (early recurrence n = 53, no recurrence
180) patients given endocrine therapy alone to compare
clinicopathological factors between these cases. Tumor
size (p < 0.001), lymph node metastasis (p = 0.002), and
tumor grade (p < 0.001) were significant in the univariate
analysis in which we compared the early recurrence and
no recurrence groups. ALDH1 expression was not a pre-
dictor of early recurrence in these patients receiving
endocrine therapy alone (p = 0.224) (Table 6).
Survival after distant recurrence
We analyzed 318 cases (early recurrence n = 184 [58 %],
late recurrence 134 [42 %]) to compare overall survival
from the time of recurrence detection between ALDH1-
positive and ALDH1-negative cases (Fig. 2). The median
follow-up duration from the detection of recurrence
until death due to breast cancer was 39 (0–141) months
in the early recurrence group and 34 (0–89) months in
the late recurrence group. The Kaplan-Meier method
showed a significant difference between ALDH1-positive
and ALDH1-negative cases (p = 0.019). Moreover, the
Kaplan-Meier method revealed a trend for higher ALDH1
expression in the early recurrence group (p = 0.082), while
there was no difference in the late recurrence group
(p = 0.27). Univariate analysis of all cases with recur-
rence revealed ALDH1 expression, nodal metastasis,
and tumor grade to be significant prognostic factors. We
selected significant parameters (p < 0.20) from among
various conventional confounding factors and performed
a multivariate analysis in which nodal metastasis, PgR,
tumor grade, and Ki-67 expression served as categorical
variables. In this multivariate analysis, lymph node metas-
tasis (p = 0.036) and tumor grade (p = 0.038) were found
to be independent prognostic factors, while ALDH1 ex-
pression was not (p = 0.059) (Table 7).
Discussion
Our results provide important insight into the chemore-
sistant nature of cancer stem cells. Furthermore, inten-
sive chemotherapy might alter the significance of the
ALDH1 marker in clinical settings. Although several
previous studies have suggested an association between
ALDH1 and clinical outcomes in breast cancer, our
analyses showed much higher ALDH1 expression in
early recurrence cases of patients receiving both endo-
crine therapy and chemotherapy, as compared with
recurrence-free patients. Furthermore, ALDH1 was as-
sociated with an aggressive phenotype in the early re-
currence group. We speculate that ALDH1 has the
capacity to induce chemoresistance of highly prolifera-
tive breast cancer cells, which might explain why we
Table 4 Univariate and multivariate analyses for late recurrence in all cases (late vs no recurrence)
Late vs no recurrence
Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 1.689 (0.883–3.164) 0.110 1.507 (0.738–2.998) 0.253
Bilateral breast cancer absent/present 17.136 (4.645–110.57) <0.001 18.952 (4.812–126.55) <0.001
Menopausal status pre/post 0.745 (0.493–1.121) 0.159 0.731 (0.464–1.144) 0.171
Tumor size, ≤20/>20 mm 2.854 (1.878–4.387) <0.001 2.356 (1.495–3.749) <0.001
Nodal metastasis negative/positive 3.442 (2.193–5.421) <0.001 2.940 (1.809–4.790) <0.001
Tumor grade 1 or 2/3 1.707 (1.001–2.877) 0.046 1.316 (0.727–2.339) 0.358
ALDH1 aldehyde dehydrogenase 1
Table 5 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy and chemotherapy
(early vs no recurrence)
Early vs no recurrence in combined therapy group
Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 4.054 (1.797–10.080) <0.001 4.625 (1.881–12.474) <0.001
Age, ≤50/>50 years 0.612 (0.349–1.067) 0.083 0.623 (0.330–1.164) 0.138
Tumor size, ≤20/>20 mm 2.553 (1.336–5.036) 0.004 2.130 (1.018–4.601) 0.044
Nodal metastasis negative/positive 4.357 (2.430–7.979) <0.001 3.856 (2.026–7.519) <0.001
Progesterone receptor staining, <20 %/≥20 % 1.035 (0.593–1.807) 0.903 Not selected
Ki-67 staining, <20 %/≥20 % 1.592 (0.858–2.983) 0.140 0.791 (0.377–1.634) 0.529
Tumor grade 1 or 2/3 2.625 (1.285–5.595) 0.007 2.098 (0.940–4.848) 0.070
ALDH1 aldehyde dehydrogenase 1
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identified several early recurrence cases among those
patients who had received adjuvant chemotherapy for
ER-positive/HER2-negative breast tumors.
The reported percentages of ALDH1-positive cases
range from 7.0 % to 59 % [2, 6, 13, 14, 16–26]. This
broad range may reflect differences in cutoff points,
sampling methods, and study populations among stud-
ies. Ricardo et al. reported ALDH1 expression rates in
different breast cancer subtypes [27]. The rates were
5.1 % in the luminal A, 12.2 % in the luminal B, and
25 % in the basal types, while the rate was 12.29 % in
the HER2 type. In the present study, the rates of ALDH1
positivity at a 1 % cutoff value were 18.4 %, 13.4 %, and
8.4 % in patients with early, late, and no recurrence,
respectively, among those with ER-positive/HER2-nega-
tive breast cancer. We found a significant difference in
ALDH1 expression between the early recurrence patients,
at the time of recurrence, and those who remained
recurrence-free. We also investigated the time from the
detection of recurrence until death due to breast cancer
according to ALDH1 expression. Univariate, but not
multivariate, analysis showed patients with ALDH1-
positive breast cancer to have a shorter survival time. This
observation suggests that the presence of ALDH1-positive
cancer stem cells correlates with early recurrence and
shorter survival. Researchers in another study found pa-
tients with ALDH1-positive tumors to have poorer out-
comes than those with ALDH1-negative tumors [6, 20, 26,
Table 6 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy alone (early vs no recurrence)
Early vs no recurrence in endocrine therapy group
Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 1.804 (0.651–4.609) 0.244 Not selected
Age, ≤50/>50 years 0.996 (0.526–1.932) 0.992 Not selected
Tumor size, ≤20/>20 mm 6.182 (3.208–12.383) <0.001 4.910 (2.469–10.076) <0.001
Nodal metastasis negative/positive 3.344 (1.543–7.181) 0.002 2.894 (1.229–6.777) 0.002
Progesterone receptor staining, <20 %/≥20 % 0.708 (0.382–1.313) 0.272 Not selected
Ki-67 staining, <20 %/≥20 % 1.441 (0.619–3.159) 0.383 Not selected
Tumor grade 1 or 2/3 2.615 (1.666–4.128) <0.001 2.820 (1.296–6.111) <0.001
ALDH1 aldehyde dehydrogenase 1
(a) (b)
(c)
ALDH1+ ALDH1+
ALDH1+
ALDH1 -
ALDH1 -
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Fig. 2 Survival time from recurrence detection until death due to breast cancer. ALDH1 aldehyde dehydrogenase 1. a all cases with recurrence.
b early recurrence cases. c late recurrence cases
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28–31]. However, the authors of other reports noted no
association of ALDH1 expression with poor outcomes [13,
21, 32, 33].
The differences among study results may be attribut-
able to differences in sample sizes, follow-up periods, tis-
sue microarray use, and use of various cutoff values for
ALDH1 staining. Yoshioka et al. highlighted the import-
ance of long-term follow-up, of employing a low cutoff
value, and of not using tissue microarrays for evaluating
ALDH1 expression [29]. In the present study, we exam-
ined the data of 639 patients, many of whom were ob-
served for at least 10 years. We used an ALDH1 cutoff
value of 1 %, which was lower than cutoffs employed in
most other studies. We used immunohistochemically
stained sections, examined whole sections, and evaluated
one hot spot in each section. In a previous report, Tsang
et al. reported ALDH1 alone not to be an independent
prognostic factor for luminal (ER-positive, HER2-
positive or HER2-negative) breast cancers [34]. However,
they used tissue microarray slides for IHC staining and
used an ALDH1 cutoff value of 5 %. Tissue microarray
slides might be of limited utility for detecting minor
populations of cancer stem cells. To identify such popu-
lations, we screened whole sections and evaluated a
cluster of cancer stem cells in one hot spot. These
methods might be optimal for identifying patient popu-
lations with a poor prognosis. Further study is needed
to identify the optimal means of determining how cancer
stem cells impact prognosis. It is necessary to identify
populations of cancer stem cells potentially associated
with a poor prognosis.
In a previous study, the effect of ALDH1 on clinical
outcomes was found to be stronger in a lymph node
metastasis-positive subgroup and a neoadjuvant chemo-
therapy setting [2, 14, 19, 23, 29, 30, 35]. In an in vitro
study, cancer stem cells showed chemoresistance traits
[7, 35]. Large tumor burden, locally advanced tumor, epi-
thelial-mesenchymal transition, high cellular proliferation,
and adjuvant and neoadjuvant settings might augment the
role of cancer stem cells in breast cancer recurrence. There-
fore, we analyzed these data in a subgroup receiving both
endocrine therapy and chemotherapy in the adjuvant set-
ting. These subgroup analyses showed higher ALDH1 ex-
pression in early recurrence patients receiving both
endocrine therapy and chemotherapy, as compared
with recurrence-free patients. However, there was no
significant difference in those receiving endocrine therapy
alone. These findings highlight ALDH1 as a detoxifying
enzyme, suggesting that ALDH1-positive cells may con-
tribute to the development of resistance to adjuvant che-
motherapeutic agents.
Finally, the relationships between ALDH1 protein ex-
pression and clinicopathological factors influencing ER-
positive/HER2-negative breast cancers were investigated.
In a previous study, ALDH1-positive tumors were found
to have aggressive phenotypes, such as triple-negative,
HER2-positive, high histological grade, high Ki-67 expres-
sion, and advanced TNM stage [13, 17, 18, 27, 28, 34, 36].
We found ALDH1-positive tumors to be significantly as-
sociated with high Ki-67 and lymph node metastasis in
cases with early recurrence. Morimoto et al. reported that
cells staining for MIB-1 did not correspond to those
staining for ALDH1 [13]. One of the most important
breast cancer markers is Ki-67, which predicts poor
outcomes and identifies which patients would benefit
from adjuvant chemotherapy. Combining the features
of cancer stem cells and high proliferative activity might
allow the identification of a group prone to early recur-
rence. However, according to a report by Liu et al., micro-
array analysis revealed ALDH1-positive cells to express
higher levels of Ki-67 than ALDH1-negative cells [12].
ALDH1-positive breast cancer stem cells are associated
with a proliferative state. These epithelial proliferative
traits might contribute to breast cancer recurrence. Alter-
natively, quiescent ALDH1-positive tumor cells might be
less likely to proliferate. Furthermore, Tsang et al. reported
that basal marker expression can enhance the prognostic
value of cancer stem cells in luminal (ER-positive, HER2-
Table 7 Univariate and multivariate analyses for survival time from recurrence detection until death due to breast cancer
Survival time
Univariate analysis p Value Multivariate analysis p Value
ALDH1, 1 %/>1 % 1.552 (1.057–2.218) 0.025 1.451 (0.985–2.085) 0.059
Age, ≤50/>50 years 1.160 (0.856–1.581) 0.338 Not selected
Bilateral breast cancer absent/present 0.813 (0.438–1.376) 0.438 Not selected
Tumor size, ≤20/>20 mm 1.062 (0.764–1.503) 0.721 Not selected
Nodal status negative/positive 1.500 (1.109–2.032) 0.008 1.387 (1.020–1.890) 0.036
Progesterone receptor staining, <20 %/≥20 % 0.789 (0.582–1.072) 0.130 0.778 (0.572–1.060) 0.111
Ki-67 staining, <20 %/≥20 % 1.270 (0.888–1.781) 0.184 1.208 (0.839–1.706) 0.301
Tumor grade 1 or 2/3 1.519 (1.080–2.105) 0.016 1.438 (1.019–1.999) 0.038
ALDH1 aldehyde dehydrogenase 1
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positive or HER2-negative) breast cancers [34]. Import-
antly, breast cancer is a heterogeneous disease. Probably,
with regard to breast cancer traits, the significance of
ALDH1-positive cancer cells in terms of contributing to
prognosis also varies among tumor types. It is necessary
to understand the heterogeneity of cancer stem cells (i.e.,
which cell types can form metastatic nodules and which
cannot) to identify subgroups with metastatic potential
and a poorer prognosis.
The major limitation of the present study is its retro-
spective design. Also, the patients were treated with vari-
ous forms of adjuvant therapy that might have affected
both recurrences and outcomes. Therefore, additional
prospective studies with well-planned cohorts are needed
to confirm our findings.
Conclusions
We identified more ALDH1-positive cases among patients
with early recurrence of ER-positive/HER2-negative breast
cancer than among those who remained recurrence-free
for at least 10 years. In these groups, ALDH1-positive
cases had an aggressive phenotype. Patients with ALDH1-
positive breast cancer also tended to have a shorter sur-
vival time. Further study is needed to understand the
heterogeneity of cancer stem cells and to confirm their
role in the development of resistance to chemotherapy.
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